Tag: licensing
-
Start-Up Developing Immunometabolism Therapies, Gains $30M Funding
A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells.
-
Biotech in $3.7B Licensing Deal for Hepatitis-B
A biotechnology company developing therapies that silence the actions of disease-causing genes is licensing its treatment program for hepatitis-B to Janssen Pharmaceuticals.
-
Virtual Reality Therapy Company Gains $5.1M in Early Funds
A company in the U.K. developing automated treatments for phobias using immersive virtual reality is raising £3.2 million ($US 5.1 million) in its first venture funding round.
-
Gilead Gains Genome-Editing Hepatitis B Therapy
Biopharmaceutical company Gilead Sciences is acquiring a genome-editing technology for treating hepatitis-B, a viral disease affecting the liver.
-
Appeals Court Backs Broad Institute in Crispr Case
A U.S. appeals court supported the Broad Institute’s claims it invented a separate Crispr technology from University of California, affirming a previous U.S. patent office ruling.
-
Genentech Gains Modular Engineered Antibodies in $5B Deal
A developer of synthetic antibodies that invoke the immune system is partnering with the biopharmaceutical company Genentech to design new therapies for blood-related and solid tumor cancers.
-
Baby Box Technology for Sick Newborns Licensed to Start-Up
A start-up company is gaining the rights to a technology that helps the breathing of infants suffering from withdrawal from drugs taken by their mothers, and other disruptive conditions.
-
Pfizer, Biotech Partner on RNA Flu Vaccine
A biotechnology company in Germany and drug maker Pfizer are developing a vaccine to prevent seasonal influenza using messenger RNA that instructs cells on production of proteins.
-
Start-Up Developing Regenerative Liver Disease Treatments
A new enterprise founded by scientists, is underway developing treatments for advanced liver disorders that combine new drugs with cell and gene therapies to restore or replace liver functions.
-
Allergan Licensing Crispr for Inherited Eye Disease
Drug maker Allergan is acquiring the rights from Editas Medicine to develop an application of the genome-editing technology Crispr for the inherited eye disease Leber congenital amaurosis type 10.